Enzymotec Ltd. (NASDAQ:ENZY) Under Analyst Spotlight

Xavier Trudeau
Août 3, 2017

News headlines about Enzymotec (NASDAQ:ENZY) have been trending very positive on Tuesday, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Enzymotec earned a news sentiment score of 0.12 on Accern's scale. Accern also gave media coverage about the biotechnology company an impact score of 92 out of 100, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near term. 108,786 shares of the stock traded hands. Enzymotec has a 1-year low of $5.20 and a 1-year high of $9.32. On November 17 the company was set at "Market Perform" according to a Wells Fargo report which is down from the previous "Outperform" rating. It is trading at $9.80 a tad higher than the 50 day moving average of $7.80 and just a bit higher than the 200 day moving average of $8.36. Enzymotec Ltd (NASDAQ:ENZY) has risen 10.01% since August 1, 2016 and is uptrending. The biotechnology company reported $0.03 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.06 by $0.03. The business had revenue of $12 million during the quarter, compared to analyst estimates of $14.23 million. Next quarter's EPS is expected be $0.07 and the next full year EPS is projected to be $0.43.

Among 3 analysts covering Enzymotec (NASDAQ:ENZY), 2 have Buy rating, 0 Sell and 1 Hold.

Enzymotec (NASDAQ ENZY) traded up 4.26% during mid-day trading on Wednesday, hitting $9.80. If you are viewing this story on another publication, it was stolen and reposted in violation of United States & global trademark and copyright laws.

Paulson & Co. Inc. owns $35.54 million in Enzymotec Ltd., which represents roughly 16.65% of the company's market cap and approximately 65.82% of the institutional ownership. The Business's technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Firm operates in two divisions: Nutrition segment and VAYA Pharma segment. Both of the Business's segments offer a range of products that leverage its lipid-related offerings.

D'autres rapports CampDesrEcrues

Discuter de cet article

SUIVRE NOTRE JOURNAL